Prudential Financial Inc Replimune Group, Inc. Transaction History

Prudential Financial Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$5.01 - $9.46 $8,517 - $16,082	-1,700 Reduced 3.82%	42,820 $385,000
Q1 2024 May 14, 2024	SELL	$6.87 - $9.31 $69,593 - $94,310	-10,130 Reduced 18.54%	44,520 $363,000
Q4 2023 Feb 13, 2024	BUY	$6.75 - $16.18 $368,887 - $884,237	54,650 New	54,650 $460,000
Q4 2021 Feb 14, 2022	SELL	$25.43 - $34.25 $489,273 - $658,970	-19,240 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$28.98 - $39.54 $304,724 - $415,763	10,515 Added 120.52%	19,240 $570,000
Q2 2020 Aug 12, 2020	BUY	$9.76 - $25.95 $85,156 - $226,413	8,725 New	8,725 $216,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $709M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.